Chronic Lymphocytic Leukemia News and Research

RSS

Chronic Lymphocytic Leukemia (CLL) is the most common form of leukemia in adults. According to the American Cancer Society, approximately 8,000 patients will be diagnosed this year. More than 60,000 people in the U.S. currently have CLL. The disease arises in lymphocytes, a type of white blood cell that normally produces antibodies and serves important immune functions.

Phase I trial shows safety of investigational drug in treating chronic lymphocytic leukemia

Reporting results from a first-in-human phase I clinical trial, researchers at University of California San Diego School of Medicine have found that treatment with cirmtuzumab, an experimental monoclonal antibody-based drug, measurably inhibited the "stemness" of chronic leukemia cancer cells - their ability to self-renew and resist terminal differentiation and senescence.

1 Jun 2018

Researchers complete genomic map of chronic lymphocytic leukemia

Researchers have created a high-resolution map of the entire epigenome of chronic lymphocytic leukemia, the most common form of leukemia.

23 May 2018

Celgene to share new and updated data around novel hematological therapies

Celgene Corporation today announced that data from a broad range of early and late stage studies evaluating Celgene investigational agents and investigational uses of marketed products will be presented at the 23rd European Hematology Association annual meeting in Stockholm, Sweden, from June 14-17, 2018.

22 May 2018

Researchers test new cancer research model that may reduce cost and speed up studies

A new model for improving how clinical trials are developed and conducted by bringing together academic cancer experts and pharmaceutical companies is being tested by research experts at The University of Texas MD Anderson Cancer Center.

15 May 2018

New T cell biomarker could be much-needed patient-selection tool for CAR T cell therapy

Penn Medicine researchers may have found the reason why some patients with advanced chronic lymphocytic leukemia don't respond to chimeric antigen receptor T cell therapy, and the answer is tied to how primed patients' immune systems are before the therapy is administered.

30 Apr 2018

Two immune checkpoint inhibitors efficiently block leukemia development in preclinical tests

Chronic lymphocytic leukemia is a hematological malignancy that originates in the blood-forming cells of the bone marrow and spreads to other organs through the bloodstream.

17 Apr 2018

Research reveals immune suppressive role of soluble antibodies in tumor progression

Wistar researchers have found that soluble antibodies promote tumor progression by inducing accumulation of myeloid-derived suppressor cells (MDSCs) in pre-clinical cancer models. Results were published online in Cancer Immunology Research.

13 Apr 2018

Scripps Florida researchers awarded $2.875 million to destroy common form of leukemia

Christoph Rader, PhD, associate professor at the Florida campus of The Scripps Research Institute, has been awarded a $2.875 million, five-year grant from the National Cancer Institute to develop unique antibody-drug conjugates engineered to eradicate one of the most common forms of leukemia, chronic lymphocytic leukemia

10 Apr 2018

Study reveals a loophole in treatment of chronic lymphocytic leukemia

A team of researchers in Italy and Austria has determined that a drug approved to treat chronic lymphocytic leukemia (CLL) may be less effective in a particular subset of patients.

4 Jan 2018

FDA researchers find underrepresentation of adults aged 75 years and older in blood cancer clinical trials

In the first comprehensive analysis of clinical trial enrollment among older adults with blood cancers, researchers from the U.S. Food and Drug Administration found significant gaps in participation among those aged 75 and older when considered against the incidence of these malignancies in this age group, according to research being presented today during the 59th American Society of Hematology Annual Meeting and Exposition in Atlanta.

12 Dec 2017

Study: Combination targeted therapy has high response rates in AML patients

Initial findings from a multi-national open-label phase Ib study of inhibitory drug therapy for relapsed or refractory acute myeloid leukemia (AML) have demonstrated a complete response in up to 50 percent patients say researchers at The University of Texas MD Anderson Cancer Center.

11 Dec 2017

Combination of chemotherapy and targeted drug improves response in younger CLL patients

Among younger patients newly diagnosed with chronic lymphocytic leukemia (CLL), treatment with a combination of chemotherapy and a molecularly targeted drug significantly improves response over what is typically seen with chemotherapy alone, according to an investigator-initiated multi-center phase II clinical trial.

11 Dec 2017

CAR T cell therapy shows long-lasting remissions in non-Hodgkin's lymphoma patients

In a pair of clinical trials stretching from Philadelphia to Tokyo, the chimeric antigen receptor (CAR) T cell therapy Kymriah (formerly known as CTL019) demonstrated long-lasting remissions in non-Hodgkin's lymphoma (NHL) patients.

11 Dec 2017

Study: Cancer patients willing to swap drug efficacy for reduced risk of adverse events

When choosing their preferred treatment, people with chronic lymphocytic leukemia (CLL) place the highest value on medicines that deliver the longest progression-free survival, but are willing to swap some drug efficacy for a reduced risk of serious adverse events according to a study published online in Blood Advances, a Journal of the American Society of Hematology.

22 Nov 2017

Penn researchers provide new insights into how Notch drives growth of B-cell cancers

Notch is one of the most frequently mutated genes in chronic lymphocytic leukemia (CLL), the most common leukemia in adults in the United States. It is also often mutated in other common B cell tumors, such as mantle cell lymphoma.

23 Oct 2017

Study provides detailed characterization of neurotoxicity arising from CD19 CAR T-cell therapy

New potential biomarkers and a novel algorithm could help identify patients at increased risk of suffering from severe neurotoxicity after receiving CD19 CAR T-cell therapy. The study extensively characterized common and occasionally fatal side effects of this immunotherapy.

12 Oct 2017

Tattoo ink from 15 years ago mimics lymph node cancer: Case study

A 30 year old Australian woman presented to the doctors with numerous small lumps under her arms for around two weeks. When one of the nodes were put under the microscope, the doctors found pigments from tattoo ink that she’d got 15 years back.

4 Oct 2017

UC San Diego researchers receive $18.2 million grant for B cell cancer clinical trial

The Independent Citizens Oversight Committee of the California Institute for Regenerative Medicine today unanimously approved an $18.29 million grant to University of California San Diego School of Medicine researchers to fund a phase Ib/IIa clinical trial of a novel combination drug therapy for B-cell cancers.

26 Aug 2017

FDA gives its nod to new drug Imbruvica (Ibrutinib) for chronic Graft versus Host Disease

The U.S. Food and Drug Administration (FDA) yesterday in a press release informed about the approval of Imbruvica (ibrutinib) for the treatment of adult patients with chronic graft versus host disease (cGVHD) who have previously failed with one or more treatment. This is the first drug that the FDA has given its approval to in this disease condition.

2 Aug 2017

Shaping the future of oncology treatment

Victories Over Cancer is about enabling those affected by cancer to enjoy more of life’s meaning full moments and making cancer more manageable. At Janssen, we're really thinking about the elimination of cancer, and we take a very deliberate approach to that.

2 Aug 2017

Chronic Lymphocytic Leukemia News and Research

Further Reading

Phase I trial shows safety of investigational drug in treating chronic lymphocytic leukemia

Researchers complete genomic map of chronic lymphocytic leukemia

Celgene to share new and updated data around novel hematological therapies

Researchers test new cancer research model that may reduce cost and speed up studies

New T cell biomarker could be much-needed patient-selection tool for CAR T cell therapy

Two immune checkpoint inhibitors efficiently block leukemia development in preclinical tests

Research reveals immune suppressive role of soluble antibodies in tumor progression

Scripps Florida researchers awarded $2.875 million to destroy common form of leukemia

Study reveals a loophole in treatment of chronic lymphocytic leukemia

FDA researchers find underrepresentation of adults aged 75 years and older in blood cancer clinical trials

Study: Combination targeted therapy has high response rates in AML patients

Combination of chemotherapy and targeted drug improves response in younger CLL patients

CAR T cell therapy shows long-lasting remissions in non-Hodgkin's lymphoma patients

Study: Cancer patients willing to swap drug efficacy for reduced risk of adverse events

Penn researchers provide new insights into how Notch drives growth of B-cell cancers

Study provides detailed characterization of neurotoxicity arising from CD19 CAR T-cell therapy

Tattoo ink from 15 years ago mimics lymph node cancer: Case study

UC San Diego researchers receive $18.2 million grant for B cell cancer clinical trial

FDA gives its nod to new drug Imbruvica (Ibrutinib) for chronic Graft versus Host Disease

Shaping the future of oncology treatment

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News